Combinations of targeted therapies in human cancers

por Decaudin, Didier, Le Tourneau, Christophe
Publicado 2016

Pembrolizumab in cervical cancer: latest evidence and clinical usefulness

por Borcoman, Edith, Le Tourneau, Christophe
Publicado 2017

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer

por Borcoman, Edith, Le Tourneau, Christophe
Publicado 2020

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets

por Saada-Bouzid, Esma, Le Tourneau, Christophe
Publicado 2019

Drug Development in Tissue-Agnostic Indications

por du Rusquec, Pauline, Le Tourneau, Christophe
Publicado 2021

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)

por Le Tourneau, Christophe, Raymond, Eric, Faivre, Sandrine
Publicado 2007

Hyperprogression under Immunotherapy

por Frelaut, Maxime, Le Tourneau, Christophe, Borcoman, Edith
Publicado 2019

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

por Borcoman, Edith, Marret, Gregoire, Le Tourneau, Christophe
Publicado 2021

Dose Escalation Methods in Phase I Cancer Clinical Trials

por Le Tourneau, Christophe, Lee, J. Jack, Siu, Lillian L.
Publicado 2009

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents

por Le Tourneau, Christophe, Gan, Hui K., Razak, Albiruni R. A., Paoletti, Xavier
Publicado 2012

Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis

por Moreau Bachelard, Camille, Coquan, Elodie, du Rusquec, Pauline, Paoletti, Xavier, Le Tourneau, Christophe
Publicado 2021

FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature

por Aide, Nicolas, Hicks, Rodney J., Le Tourneau, Christophe, Lheureux, Stéphanie, Fanti, Stefano, Lopci, Egesta
Publicado 2018

HDAC Inhibition to Prime Immune Checkpoint Inhibitors

por Borcoman, Edith, Kamal, Maud, Marret, Grégoire, Dupain, Celia, Castel-Ajgal, Zahra, Le Tourneau, Christophe
Publicado 2021

Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

por Gougis, Paul, Moreau Bachelard, Camille, Kamal, Maud, Gan, Hui K, Borcoman, Edith, Torossian, Nouritza, Bièche, Ivan, Le Tourneau, Christophe
Publicado 2019

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous c...

por Gilbert, Jill, Le Tourneau, Christophe, Mehanna, Hisham, Fayette, Jerome, Goswami, Trishna, Emeribe, Ugochi, Jarkowski, Anthony, Melillo, Giovanni, Siu, Lilian L
Publicado 2015

Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine

por Stoeklé, Henri-Corto, Mamzer-Bruneel, Marie-France, Frouart, Charles-Henry, Le Tourneau, Christophe, Laurent-Puig, Pierre, Vogt, Guillaume, Hervé, Christian
Publicado 2017

An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry

por Le Tourneau, Christophe, Perret, Camille, Hackshaw, Allan, Blay, Jean-Yves, Nabholz, Christoph, Geissler, Jan, Do, Thy, von Meyenn, Martina, Dienstmann, Rodrigo
Publicado 2022

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer

por Leary, Alexandra, Le Tourneau, Christophe, Varga, Andrea, Sablin, Marie-Paule, Gomez-Roca, Carlos, Guilbaud, Nicolas, Petain, Aurelie, Pavlyuk, Mariya, Delord, Jean-Pierre
Publicado 2018

De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor

por Morel, Adeline, Masliah-Planchon, Julien, Bataillon, Guillaume, Becette, Véronique, Morel, Claire, Antonio, Samantha, Girard, Elodie, Bièche, Ivan, Le Tourneau, Christophe, Kamal, Maud
Publicado 2019

Patient-reported tolerability of adverse events in phase 1 trials

por Henon, Clémence, Lissa, Delphine, Paoletti, Xavier, Thibault, Constance, Le Tourneau, Christophe, Lanoy, Emilie, Hollebecque, Antoine, Massard, Christophe, Soria, Jean-Charles, Postel-Vinay, Sophie
Publicado 2017